- 米国企業
- Edwards Lifesciences Corp
Edwards Lifesciences CorpEW
時価総額
$535.7億
PER
38.2倍
2010年 12月31日 | 2011年 12月31日 | 2012年 12月31日 | 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | |
Cash and cash equivalents | 396 | 171 | 311 | 420 | 654 | 718 | 930 | 818 | 714 | 1,179 | 1,183 | 863 | 769 | 1,144 |
Short-Term Investments | - | - | - | - | 785 | 506 | 341 | 519 | 242 | 338 | 219 | 604 | 446 | 501 |
Accounts Receivable, after Allowance for Credit Loss, Current | 277 | 284 | 321 | 303 | 288 | 315 | 366 | 422 | 457 | 544 | 515 | 582 | 643 | 775 |
Other receivables | 25 | 37 | 26 | 26 | 37 | 29 | 49 | 41 | 80 | 56 | 88 | 83 | 56 | 62 |
Inventory, Net | 204 | 261 | 281 | 309 | 297 | 340 | 397 | 555 | 607 | 641 | 802 | 727 | 876 | 1,168 |
Prepaid expenses | 35 | 35 | 42 | 47 | 49 | 45 | 46 | 61 | 54 | 59 | 75 | 85 | 110 | 147 |
Other current assets | 43 | 57 | 57 | 72 | 122 | 94 | 112 | 117 | 132 | 168 | 208 | 237 | 196 | 239 |
Total current assets | 1,033 | 1,169 | 1,292 | 1,726 | 2,295 | 2,048 | 2,240 | 2,532 | 2,287 | 2,984 | 3,091 | 3,181 | 3,096 | 4,036 |
Long-Term Investments | 25 | 22 | 21 | 22 | 241 | 380 | 532 | 567 | 506 | 586 | 802 | 1,834 | 1,239 | 584 |
Property, Plant and Equipment, Net | 270 | 304 | 373 | 422 | 443 | 483 | 580 | 680 | 868 | 1,060 | 1,395 | 1,547 | 1,633 | 1,749 |
Operating Lease, Right-of-Use Asset | - | - | - | - | - | - | - | - | - | 80 | 94 | 92 | 92 | 94 |
Goodwill | 315 | 350 | 385 | 385 | 376 | 628 | 626 | 1,127 | 1,112 | 1,168 | 1,173 | 1,168 | 1,164 | 1,254 |
Other intangible assets, net (Note 10) | - | 67 | 67 | 57 | 23 | 205 | 205 | 468 | 343 | 337 | 331 | 324 | 285 | 428 |
Deferred income taxes | - | - | - | - | - | - | - | 214 | 174 | 172 | 231 | 247 | 484 | 755 |
Other assets | 13 | 25 | 26 | 35 | 49 | 131 | 123 | 109 | 34 | 102 | 120 | 111 | 299 | 464 |
Total assets | 1,767 | 1,981 | 2,222 | 2,725 | 3,524 | 4,059 | 4,510 | 5,696 | 5,324 | 6,488 | 7,237 | 8,503 | 8,293 | 9,363 |
Accounts payable | 48 | 85 | 75 | 48 | 58 | 64 | 97 | 117 | 134 | 180 | 197 | 205 | 202 | 201 |
Accrued and other liabilities (Note 5) | - | - | - | - | - | - | - | - | - | - | - | 802 | 795 | 969 |
Operating Lease, Liability, Current | - | - | - | - | - | - | - | - | - | 26 | 27 | 26 | 26 | 25 |
Total current liabilities | 338 | 335 | 347 | 346 | 434 | 476 | 533 | 1,403 | 877 | 902 | 894 | 1,032 | 1,022 | 1,195 |
Long-term debt (Note 11) | - | - | - | 593 | 598 | 600 | 822 | 438 | 594 | 594 | 595 | 596 | 596 | 597 |
Contingent consideration liabilities (Note 12) | - | - | - | - | - | - | - | 193 | 179 | 173 | 186 | 62 | 26 | - |
Taxes Payable | - | - | - | - | - | - | - | 394 | 259 | 237 | 215 | 190 | 143 | 81 |
Operating lease liabilities (Note 6) | - | - | - | - | - | - | - | - | - | 59 | 73 | 69 | 70 | 73 |
Uncertain tax positions (Note 18) | - | - | - | 126 | 195 | 195 | 230 | 165 | 125 | 172 | 214 | 259 | 268 | 339 |
Litigation settlement accrual (Note 3) | - | - | - | - | - | - | - | - | - | - | 233 | 191 | 143 | 94 |
Other liabilities | 121 | 157 | 206 | 100 | 106 | 285 | 306 | 147 | 150 | 203 | 252 | 267 | 218 | 264 |
Total liabilities | 459 | 643 | 742 | 1,166 | 1,333 | 1,556 | 1,891 | 2,740 | 2,183 | 2,340 | 2,663 | 2,667 | 2,486 | 2,644 |
Preferred Stock, Value, Issued | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Common Stock, Value, Issued | 117 | 120 | 124 | 126 | 129 | 239 | 243 | 212 | 215 | 218 | 636 | 642 | 646 | 651 |
Additional paid-in capital | - | 301 | 489 | 671 | 878 | 947 | 1,168 | 1,167 | 1,384 | 1,623 | 1,438 | 1,700 | 1,969 | 2,274 |
Retained earnings | 1,124 | 1,361 | 1,654 | 2,046 | 2,842 | 3,337 | 3,906 | 1,962 | 2,695 | 3,742 | 4,565 | 6,068 | 7,590 | 8,992 |
Accumulated other comprehensive loss (Note 16) | -42 | -37 | -38 | -28 | -101 | -183 | -198 | -133 | -138 | -156 | -161 | -158 | -255 | -243 |
Treasury stock, at cost, 49.4 and 38.0 shares, respectively | - | - | - | - | - | - | - | - | - | - | - | - | 4,144 | 5,025 |
Total Edwards Lifesciences Corporation stockholders' equity | 1,308 | 1,338 | 1,479 | 1,559 | 2,191 | 2,503 | 2,619 | 2,956 | 3,140 | 4,148 | 4,574 | 5,836 | 5,807 | 6,719 |
Noncontrolling interest (Note 9) | - | - | - | - | - | - | - | - | - | - | - | - | - | 69 |
Total stockholders' equity | 1,308 | - | - | - | - | - | - | - | - | - | - | - | - | 6,719 |
Total liabilities and stockholders' equity | 1,767 | 1,981 | 2,222 | 2,725 | 3,524 | 4,059 | 4,510 | 5,696 | 5,324 | 6,488 | 7,237 | 8,503 | 8,293 | 9,363 |